A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma

A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma

Plasmablastic lymphoma (PBL) and plasmablastic plasma cell myeloma (PCM) have many overlapping characteristics. Clinical correlation can help make the distinction between the two entities. Human immunodeficiency virus- (HIV-) negative PBL is a rare disease, making the diagnosis more challenging. Whi...

Full description

Bibliographic Details
Main Authors: Alaina J. Kessler, Bridget K. Marcellino, Scot A. Niglio, Bruce E. Petersen, Adriana K. Malone
Format: Article
Language:English
Published: Hindawi Limited 2019-01-01
Series:Case Reports in Hematology
Online Access:http://dx.doi.org/10.1155/2019/2907317
id doaj-6d612f24a9914276a4153ed7ded0673f
record_format Article
spelling doaj-6d612f24a9914276a4153ed7ded0673f2020-11-25T00:02:27ZengHindawi LimitedCase Reports in Hematology2090-65602090-65792019-01-01201910.1155/2019/29073172907317A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic DilemmaAlaina J. Kessler0Bridget K. Marcellino1Scot A. Niglio2Bruce E. Petersen3Adriana K. Malone4Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USATisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USATisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USADepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USATisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAPlasmablastic lymphoma (PBL) and plasmablastic plasma cell myeloma (PCM) have many overlapping characteristics. Clinical correlation can help make the distinction between the two entities. Human immunodeficiency virus- (HIV-) negative PBL is a rare disease, making the diagnosis more challenging. While there is no standard of care for PBL, current recommendations include dose-adjusted EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone), with or without bortezomib. We report an aggressive case of HIV-negative plasmablastic lymphoma and discuss the challenge in establishing a diagnosis. We review the literature regarding this disease and current recommendations for treatment.http://dx.doi.org/10.1155/2019/2907317
collection DOAJ
language English
format Article
sources DOAJ
author Alaina J. Kessler
Bridget K. Marcellino
Scot A. Niglio
Bruce E. Petersen
Adriana K. Malone
spellingShingle Alaina J. Kessler
Bridget K. Marcellino
Scot A. Niglio
Bruce E. Petersen
Adriana K. Malone
A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma
Case Reports in Hematology
author_facet Alaina J. Kessler
Bridget K. Marcellino
Scot A. Niglio
Bruce E. Petersen
Adriana K. Malone
author_sort Alaina J. Kessler
title A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma
title_short A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma
title_full A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma
title_fullStr A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma
title_full_unstemmed A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma
title_sort rare presentation of hiv-negative plasmablastic lymphoma: a diagnostic dilemma
publisher Hindawi Limited
series Case Reports in Hematology
issn 2090-6560
2090-6579
publishDate 2019-01-01
description Plasmablastic lymphoma (PBL) and plasmablastic plasma cell myeloma (PCM) have many overlapping characteristics. Clinical correlation can help make the distinction between the two entities. Human immunodeficiency virus- (HIV-) negative PBL is a rare disease, making the diagnosis more challenging. While there is no standard of care for PBL, current recommendations include dose-adjusted EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone), with or without bortezomib. We report an aggressive case of HIV-negative plasmablastic lymphoma and discuss the challenge in establishing a diagnosis. We review the literature regarding this disease and current recommendations for treatment.
url http://dx.doi.org/10.1155/2019/2907317
work_keys_str_mv AT alainajkessler ararepresentationofhivnegativeplasmablasticlymphomaadiagnosticdilemma
AT bridgetkmarcellino ararepresentationofhivnegativeplasmablasticlymphomaadiagnosticdilemma
AT scotaniglio ararepresentationofhivnegativeplasmablasticlymphomaadiagnosticdilemma
AT bruceepetersen ararepresentationofhivnegativeplasmablasticlymphomaadiagnosticdilemma
AT adrianakmalone ararepresentationofhivnegativeplasmablasticlymphomaadiagnosticdilemma
AT alainajkessler rarepresentationofhivnegativeplasmablasticlymphomaadiagnosticdilemma
AT bridgetkmarcellino rarepresentationofhivnegativeplasmablasticlymphomaadiagnosticdilemma
AT scotaniglio rarepresentationofhivnegativeplasmablasticlymphomaadiagnosticdilemma
AT bruceepetersen rarepresentationofhivnegativeplasmablasticlymphomaadiagnosticdilemma
AT adrianakmalone rarepresentationofhivnegativeplasmablasticlymphomaadiagnosticdilemma
_version_ 1725437636400644096

Similar Items